Nurix Therapeutics Inc (NRIX)

$19.14 -0.35 (-1.80%)
Market Cap 1.38B
Revenue (ttm) 76.99M
Net Income (ttm) -143.95M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -186.97%
Debt to Equity Ratio 0.00
Volume 784,000
Avg Vol 954,504
Day's Range N/A - N/A
Shares Out 70.84M
Stochastic %K 66%
Beta 2.14
Analysts Strong Sell
Price Target $31.94

Latest News on NRIX

Nurix Therapeutics: Speculative Bet On BTK Degraders And Targeted Protein Modulation

Jan 9, 2025, 8:44 AM EST - 9 days ago

Nurix Therapeutics: Speculative Bet On BTK Degraders And Targeted Protein Modulation

Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 7:00 AM EST - 12 days ago

Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia

Dec 19, 2024, 7:00 AM EST - 4 weeks ago

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia

Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting

Dec 9, 2024, 6:00 PM EST - 5 weeks ago

Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting

Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting

Dec 2, 2024, 7:00 AM EST - 6 weeks ago

Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting

Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 25, 2024, 7:00 AM EST - 7 weeks ago

Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

Nov 20, 2024, 4:00 PM EST - 2 months ago

Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024

Nov 17, 2024, 10:30 AM EST - 2 months ago

Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Oct 31, 2024, 7:00 AM EDT - 2 months ago

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit

Oct 21, 2024, 4:00 PM EDT - 3 months ago

Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit

Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia

Oct 19, 2024, 8:00 AM EDT - 3 months ago

Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia

Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur

Oct 16, 2024, 4:35 PM EDT - 3 months ago

Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur

Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

Oct 11, 2024, 4:00 PM EDT - 3 months ago

Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

Nurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the American College of Rheumatology

Oct 9, 2024, 7:00 AM EDT - 3 months ago

Nurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the American College of Rheumatology

Nurix: An Attractive Early-Stage Biotech Play

Oct 8, 2024, 10:58 AM EDT - 3 months ago

Nurix: An Attractive Early-Stage Biotech Play

Nurix Therapeutics Announces Presentations at Discovery on Target Conference

Sep 30, 2024, 7:00 AM EDT - 3 months ago

Nurix Therapeutics Announces Presentations at Discovery on Target Conference

Nurix Therapeutics To Participate in Upcoming ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit

Sep 6, 2024, 7:00 AM EDT - 4 months ago

Nurix Therapeutics To Participate in Upcoming ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit

Nurix Therapeutics: Promising Science, Major Collaborations, Undifferentiated Data

Sep 4, 2024, 11:59 AM EDT - 4 months ago

Nurix Therapeutics: Promising Science, Major Collaborations, Undifferentiated Data

Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

Jul 11, 2024, 4:00 PM EDT - 6 months ago

Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case

Jun 19, 2024, 9:27 AM EDT - 7 months ago

Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case

Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)

Jun 16, 2024, 5:30 AM EDT - 7 months ago

Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)

Nurix Therapeutics Appoints Paula G. O'Connor, M.D.

May 28, 2024, 7:00 AM EDT - 8 months ago

Nurix Therapeutics Appoints Paula G. O'Connor, M.D.

Nurix Therapeutics Announces Board Chair Transition

May 20, 2024, 4:00 PM EDT - 8 months ago

Nurix Therapeutics Announces Board Chair Transition

Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)

May 14, 2024, 10:00 AM EDT - 8 months ago

Nurix Therapeutics Announces Upcoming Oral Presentation of New Data from Ongoing Clinical Trial of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)

Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference

May 7, 2024, 7:00 AM EDT - 9 months ago

Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference

Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Apr 16, 2024, 6:21 PM EDT - 9 months ago

Nurix Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering

Apr 11, 2024, 11:38 PM EDT - 10 months ago

Nurix Therapeutics Announces Pricing of Upsized $175.0 Million Public Offering

Nurix Therapeutics Announces Proposed Public Offering

Apr 11, 2024, 4:00 PM EDT - 10 months ago

Nurix Therapeutics Announces Proposed Public Offering

Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

Apr 10, 2024, 7:00 AM EDT - 10 months ago

Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies

Apr 9, 2024, 1:15 PM EDT - 10 months ago

Nurix Therapeutics Reports First Clinical Evidence of CNS Activity of NX-5948, a Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies

Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6

Apr 9, 2024, 7:00 AM EDT - 10 months ago

Nurix Therapeutics Announces Extension of Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degraders of STAT6

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Apr 3, 2024, 7:00 AM EDT - 10 months ago

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences

Apr 2, 2024, 7:00 AM EDT - 10 months ago

Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences

Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)

Mar 25, 2024, 7:00 AM EDT - 10 months ago

Nurix Therapeutics is Part of a Team of International Oncology Experts Selected as Cancer Grand Challenges Awardees to Address Pediatric Cancers Using Targeted Protein Degradation (TPD)

Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting

Mar 20, 2024, 9:40 AM EDT - 10 months ago

Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update

Feb 15, 2024, 4:00 PM EST - 1 year ago

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update

Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 Degrader

Feb 1, 2024, 4:01 PM EST - 1 year ago

Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 Degrader

Nurix Therapeutics: A Unique Approach To BTK Targeting

Jan 22, 2024, 8:50 AM EST - 1 year ago

Nurix Therapeutics: A Unique Approach To BTK Targeting

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory CLL and SLL

Jan 16, 2024, 4:01 PM EST - 1 year ago

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory CLL and SLL

Nurix Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

Jan 2, 2024, 4:01 PM EST - 1 year ago

Nurix Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference

Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton's Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting

Dec 11, 2023, 12:00 PM EST - 1 year ago

Nurix Therapeutics Presents Positive Clinical Data from Its Novel Bruton's Tyrosine Kinase (BTK) Degrader Programs, NX-5948 and NX-2127, at the 65th American Society of Hematology (ASH) Annual Meeting

Nurix Therapeutics Announces Webcast To Review Data from Its Phase 1 Clinical Trials of BTK Degraders, NX-5948 and NX-2127, Presented at the 65th American Society of Hematology (ASH) Annual Meeting

Dec 4, 2023, 4:01 PM EST - 1 year ago

Nurix Therapeutics Announces Webcast To Review Data from Its Phase 1 Clinical Trials of BTK Degraders, NX-5948 and NX-2127, Presented at the 65th American Society of Hematology (ASH) Annual Meeting

Nurix Therapeutics Announces Presentations at the 65th American Society of Hematology (ASH) Annual Meeting

Nov 2, 2023, 9:00 AM EDT - 1 year ago

Nurix Therapeutics Announces Presentations at the 65th American Society of Hematology (ASH) Annual Meeting

Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial

Nov 1, 2023, 4:01 PM EDT - 1 year ago

Nurix Therapeutics Announces Partial Clinical Hold For NX-2127 Phase 1 Trial

Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate Update

Oct 12, 2023, 4:01 PM EDT - 1 year ago

Nurix Therapeutics Reports Third Quarter Fiscal 2023 Financial Results and Provides a Corporate Update

Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update

Jul 13, 2023, 4:01 PM EDT - 1 year ago

Nurix Therapeutics Reports Second Quarter Fiscal 2023 Financial Results and Provides a Corporate Update

Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications

Jun 14, 2023, 7:00 AM EDT - 1 year ago

Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications

Nurix Therapeutics to Participate in the 2023 RBC Capital Markets Global Healthcare Conference

May 9, 2023, 4:01 PM EDT - 1 year ago

Nurix Therapeutics to Participate in the 2023 RBC Capital Markets Global Healthcare Conference

Nurix Therapeutics Presents Data at the American Association for Cancer Research (AACR) Annual Meeting Highlighting Activity of its BTK Targeted Protein Degraders, NX-2127 and NX-5948, against a Broad Range of BTKi Resistance Mutations

Apr 17, 2023, 2:30 PM EDT - 1 year ago

Nurix Therapeutics Presents Data at the American Association for Cancer Research (AACR) Annual Meeting Highlighting Activity of its BTK Targeted Protein Degraders, NX-2127 and NX-5948, against a Broad Range of BTKi Resistance Mutations

Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results and Provides a Corporate Update

Apr 13, 2023, 4:01 PM EDT - 1 year ago

Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results and Provides a Corporate Update